Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Christoph Wanner"'
Autor:
Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, CARMELINA® investigators
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-15 (2018)
Abstract Background Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial aims to evaluat
Externí odkaz:
https://doaj.org/article/4f753d01958c432990f07fa12eea7bb6
Autor:
Colin Baigent, JonathanR. Emberson, Richard Haynes, William G. Herrington, Parminder Judge, Martin J. Landray, Kaitlin J. Mayne, Sarah Y.A. Ng, David Preiss, Alistair J. Roddick, Natalie Staplin, Doreen Zhu, Stefan D. Anker, Deepak L. Bhatt, Martina Brueckmann, Javed Butler, David Z.I. Cherney, Jennifer B. Green, Sibylle J. Hauske, Hiddo J.L. Heerspink, Silvio E. Inzucchi, Meg J. Jardine, Chih-Chin Liu, Kenneth W. Mahaffey, Finnian R. McCausland, Darren K. McGuire, John J.V. McMurray, Bruce Neal, Brendon L. Neuen, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Faiez Zannad
Publikováno v:
The Lancet. 400:1788-1801
Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atheroscl
Autor:
Cheng Wang, Anuraag R. Kansal, Anastasia Ustyugova, Matthew Stargardter, Odette Reifsnider, Egon Pfarr, Christoph Wanner, Sarah Brand, Effie Kuti, Audrey Koitka-Weber
Publikováno v:
American Journal of Kidney Diseases. 79:796-806
Rationale & Objective Benefits of sodium-glucose co-transporter 2 inhibitors on kidney outcomes have been demonstrated in clinical trials. Among patients with type 2 diabetes and established cardiovascular (CV) disease enrolled in EMPA-REG Outcome St
Autor:
Brendon L. Neuen, Megumi Oshima, Rajiv Agarwal, Clare Arnott, David Z. Cherney, Robert Edwards, Anna Maria Langkilde, Kenneth W. Mahaffey, Darren K. McGuire, Bruce Neal, Vlado Perkovic, Annpey Pong, Marc S. Sabatine, Itamar Raz, Tadashi Toyama, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Bernard Zinman, Hiddo J.L. Heerspink
Publikováno v:
Circulation, 145(19), 1460-1470. LIPPINCOTT WILLIAMS & WILKINS
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney d
Autor:
Anne Pernille Ofstad, Afshin Salsali, Erich Bluhmki, Martin Schumacher, Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Stefan Hantel, Kristin Ohneberg, Jyothis T. George, Claudia Schmoor, David Fitchett, Faiez Zannad, Bernard Zinman
Publikováno v:
ESC Heart Failure
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
International audience; Aims: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardio
Autor:
Faiez, Zannad, João Pedro, Ferreira, John, Gregson, Bettina Johanna, Kraus, Michaela, Mattheus, Sibylle Jenny, Hauske, Javed, Butler, Gerasimos, Filippatos, Christoph, Wanner, Stefan D, Anker, Stuart J, Pocock, Milton, Packer
Publikováno v:
European Journal of Heart Failure
European Journal of Heart Failure, 2022, 24 (10), pp.1829-1839. ⟨10.1002/ejhf.2578⟩
European Journal of Heart Failure, 2022, 24 (10), pp.1829-1839. ⟨10.1002/ejhf.2578⟩
International audience; Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) may induce an early post-initiation decrease of estimated glomerular filtration rate (eGFR), which does not impact the SGLT2i benefits. The occurrence, characteristics,
Autor:
Odd Erik Johansen, Christoph Wanner, Isabella Zwiener, Subodh Verma, Javed Butler, Jyothis T. George, Bernard Zinman, Silvio E. Inzucchi, C. David Mazer, Anne Pernille Ofstad
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To determine the relationship between polyvascular disease and risk of hospitalization for heart failure (HHF) and cardiovascular (CV) death in the EMPA‐REG OUTCOME population, and the relationship of kidney dysfunction co‐existent with polyv
Autor:
Christoph Wanner, Stefan D. Anker, Waheed Jamal, Stuart J. Pocock, Gerasimos Filippatos, Milton Packer, Martina Brueckmann, Faiez Zannad, Javed Butler, João Pedro Ferreira, Cordula Zeller
Publikováno v:
New England Journal of Medicine. 385:1531-1533
Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2....
Autor:
Katherine R. Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J. Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C. Wheeler
OBJECTIVE To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3–4) enrolled in clinical trials. RESEARCH DESIGN AND METHODS This analysis pooled data from 19 randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a5aaa65b93ecd8a970deb5c139c723
https://doi.org/10.2337/figshare.19465484
https://doi.org/10.2337/figshare.19465484
Autor:
Janet B McGill, Hermann Haller, Prabir Roy-Chaudhury, Andrea Cherrington, Takashi Wada, Christoph Wanner, Linong Ji, Peter Rossing
Publikováno v:
McGill, J B, Haller, H, Roy-Chaudhury, P, Cherrington, A, Wada, T, Wanner, C, Ji, L & Rossing, P 2022, ' Making an impact on kidney disease in people with type 2 diabetes : the importance of screening for albuminuria ', BMJ open diabetes research & care, vol. 10, no. 4 . https://doi.org/10.1136/bmjdrc-2022-002806
Albuminuria is useful for early screening and diagnosis of kidney impairment, especially in people with pre-diabetes or type 2 diabetes (T2D), which is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD), associated